{
    "clinical_study": {
        "@rank": "152872", 
        "arm_group": [
            {
                "arm_group_label": "Icotinib of Routine Dose", 
                "arm_group_type": "Active Comparator", 
                "description": "Oral Drug icotinib 125 mg three times per day"
            }, 
            {
                "arm_group_label": "Icotinib of High Dose", 
                "arm_group_type": "Experimental", 
                "description": "Oral Drug icotinib 250 mg three times per day"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary purposes of this study are to assess the safety and efficacy of using high doses\n      of the drug Icotinib (Conmana) as a way to treat patients with non-small cell lung cancer\n      that achieve stable disease after 8 weeks routine therapy."
        }, 
        "brief_title": "Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "NSCLC", 
        "condition_browse": {
            "mesh_term": "Carcinoma, Non-Small-Cell Lung"
        }, 
        "detailed_description": {
            "textblock": "This is a multi-center phase II randomized controlled study to assess the safety and\n      efficacy of using high doses of the drug Icotinib (Conmana) as a way to treat patients with\n      non-small cell lung cancer that achieve stable disease after 8 weeks routine therapy by PFS,\n      as well as OS and DCR. The adverse events and adverse reaction are evaluated as well."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically confirmed stage IIIB/IV lung cancer(exclude patients\n             confirmed by sputum cytology)\n\n          -  No previous targeted treatment such as gefitinib, erlotinib.\n\n          -  With a measurable disease(longest diameters >=10mm with Spiral computed tomography\n             (CT)and >=20mm with conventional CT) at least according to RECIST Criteria\n\n          -  WHO performance status(PS)<= 2\n\n          -  N>=1.5\u00d7109/L, Plt>=1.0\u00d7109/L,Hb>=10g/dL;AST&ALT should <3ULN(without liver\n             metastasis) or <5ULN(with liver metastasis).TBIL<=1.5ULN.\n\n          -  Signed and dated informed consent before the start of specific protocol procedures.\n\n        Exclusion Criteria:\n\n          -  Allergic to icotinib\n\n          -  Patients with metastatic brain tumors with symptoms.\n\n          -  Experience of Anti-EGFR(the epidermal growth factor receptor) Monoclonal Antibody or\n             small molecular compounds therapy such as gefitinib, erlotinib or Cetuximab.\n\n          -  Severe systemic disease out of control such as unstable or uncompensated\n             respiratory,cardiac,liver,renal diseases."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "180", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01690390", 
            "org_study_id": "BD-IV-43"
        }, 
        "intervention": [
            {
                "arm_group_label": "Icotinib of Routine Dose", 
                "description": "Icotinib of routine dose: 125 mg is administered orally three times per day.", 
                "intervention_name": "Icotinib of routine dose", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Icotinib", 
                    "Comana", 
                    "BPI-2009"
                ]
            }, 
            {
                "arm_group_label": "Icotinib of High Dose", 
                "description": "Icotinib: 250 mg is administered orally three times per day.", 
                "intervention_name": "Icotinib of high dose", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Icotinib", 
                    "Comana", 
                    "BPI-2009"
                ]
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "December 19, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Huang Cheng, M.D.", 
                    "phone": "0086-13905010397"
                }, 
                "facility": {
                    "address": {
                        "city": "Fuzhou", 
                        "country": "China", 
                        "state": "Fujian", 
                        "zip": "350014"
                    }, 
                    "name": "Fujian Provincal Cancer Hospital"
                }, 
                "investigator": {
                    "last_name": "Huang Cheng, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Cui Tongjian, M.D.", 
                    "phone": "0086-13905920326"
                }, 
                "facility": {
                    "address": {
                        "city": "Fuzhou", 
                        "country": "China", 
                        "state": "Fujian", 
                        "zip": "350001"
                    }, 
                    "name": "Fujian Provincal Hospital"
                }, 
                "investigator": {
                    "last_name": "Cui Tongjian, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Chen Qun, M.D.", 
                    "phone": "0086-13860669883"
                }, 
                "facility": {
                    "address": {
                        "city": "Fuzhou", 
                        "country": "China", 
                        "state": "Fujian", 
                        "zip": "350000"
                    }, 
                    "name": "Fujian Hospital for Chest Tumors & Tuberculosis Diseases"
                }, 
                "investigator": {
                    "last_name": "Chen Qun, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ke Mingyao, M.D.", 
                    "phone": "0086-13860166866"
                }, 
                "facility": {
                    "address": {
                        "city": "Xiamen", 
                        "country": "China", 
                        "state": "Fujian", 
                        "zip": "361024"
                    }, 
                    "name": "The second hospital of Xiamen City"
                }, 
                "investigator": {
                    "last_name": "Ke Mingyao, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Wu Lin, M.D.", 
                    "phone": "0086-13706671349"
                }, 
                "facility": {
                    "address": {
                        "city": "Changsha", 
                        "country": "China", 
                        "state": "Hunan", 
                        "zip": "410006"
                    }, 
                    "name": "Hunan Provincal Cancer Hospital"
                }, 
                "investigator": {
                    "last_name": "Wu Lin, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Yu Jingrui, M.D.", 
                    "phone": "0086-13551237583"
                }, 
                "facility": {
                    "address": {
                        "city": "Chengdu", 
                        "country": "China", 
                        "state": "Sichuan", 
                        "zip": "610041"
                    }, 
                    "name": "The Second People's Hospital of Sichuan"
                }, 
                "investigator": {
                    "last_name": "Yu Jingrui, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "zyp@medmail.com.cn", 
                    "last_name": "Zhang Yi Ping, M.D.", 
                    "phone": "0086-13750881678"
                }, 
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China", 
                        "state": "Zhejiang", 
                        "zip": "310000"
                    }, 
                    "name": "Zhejiang Cancer Hospital"
                }, 
                "investigator": {
                    "last_name": "Zhang Yi Ping, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "drzjy@163.com", 
                    "last_name": "Zhou Jianying, M.D.", 
                    "phone": "0086-13750881678"
                }, 
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China", 
                        "state": "Zhejiang", 
                        "zip": "310000"
                    }, 
                    "name": "The First Affiliated Hospital of Medical School of Zhejiang University"
                }, 
                "investigator": {
                    "last_name": "Zhou Jianying, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "hhjj@medmail.com.cn", 
                    "last_name": "Huang Jianjin, M.D.", 
                    "phone": "0086-13989889688"
                }, 
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China", 
                        "state": "Zhejiang", 
                        "zip": "310000"
                    }, 
                    "name": "The Second Affiliated Hospital of Zhejiang University School of Medicine"
                }, 
                "investigator": {
                    "last_name": "Huang Jianjin, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "panhongming@tom.com", 
                    "last_name": "Pan Minghong, M.D.", 
                    "phone": "0086-57186006", 
                    "phone_ext": "922"
                }, 
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China", 
                        "state": "Zhejiang", 
                        "zip": "310000"
                    }, 
                    "name": "Sir Run Run Shaw Hospital"
                }, 
                "investigator": {
                    "last_name": "Pan Minghong, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "llq99999@yahoo.com.cn", 
                    "last_name": "Lu Li Qin, M.D.", 
                    "phone": "0086-13858039628"
                }, 
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China", 
                        "state": "Zhejiang", 
                        "zip": "310014"
                    }, 
                    "name": "Zhejiang Provincial People's Hospital"
                }, 
                "investigator": {
                    "last_name": "Lu Li Qin, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China", 
                        "state": "Zhejiang", 
                        "zip": "310006"
                    }, 
                    "name": "Zhejiang Traditional Chinese Medical Hospital"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China", 
                        "state": "Zhejiang", 
                        "zip": "310007"
                    }, 
                    "name": "Zhejiang Hospital"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Shen Weiyu, M.D.", 
                    "phone": "0086-13805876129"
                }, 
                "facility": {
                    "address": {
                        "city": "Ningbo", 
                        "country": "China", 
                        "state": "Zhejiang", 
                        "zip": "315046"
                    }, 
                    "name": "Ningbo Medical Treatment Center Lihuili Hospital"
                }, 
                "investigator": {
                    "last_name": "Shen Weiyu, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Guo Jianxin, M.D.", 
                    "phone": "0086-13605741696"
                }, 
                "facility": {
                    "address": {
                        "city": "Ningbo", 
                        "country": "China", 
                        "state": "Zhejiang", 
                        "zip": "315040"
                    }, 
                    "name": "Yinzhou People's Hospital"
                }, 
                "investigator": {
                    "last_name": "Guo Jianxin, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Hu Wei, M.D.", 
                    "phone": "0086-13606657129"
                }, 
                "facility": {
                    "address": {
                        "city": "Taizhou", 
                        "country": "China", 
                        "state": "Zhejiang", 
                        "zip": "317000"
                    }, 
                    "name": "Taizhou Hospital of Zhejiang Province"
                }, 
                "investigator": {
                    "last_name": "Hu Wei, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Li Wenfeng, M.D.", 
                    "phone": "0086-13968840592"
                }, 
                "facility": {
                    "address": {
                        "city": "Wenzhou", 
                        "country": "China", 
                        "state": "Zhejiang", 
                        "zip": "325000"
                    }, 
                    "name": "The First Affiliated Hospital of Wenzhou Medical College"
                }, 
                "investigator": {
                    "last_name": "Li Wenfeng, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-label, Randomized, Multicenter, Phase II Trial to Evaluate the Safety and Efficacy of Dose Escalation of Icotinib in Advanced or Metastatic NSCLC Patients After 8 Weeks Routine Therapy Evaluated as Stable Disease", 
        "overall_contact": {
            "email": "zyp@medmail.com.cn", 
            "last_name": "Zhang Yi Ping, M.D.", 
            "phone": "0086-13750881678"
        }, 
        "overall_official": {
            "affiliation": "Zhejiang Cancer Hospital", 
            "last_name": "Zhang Yi Ping, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "A duration from randomization date to disease progression(as defined by RECIST) or death. If a participant are known to have progressed, the time to progression is defined as the time from the date of randomization to the date of progression. Otherwise, a participant will be censored at the last date they are known not to be progressed.", 
            "measure": "Progression Free Survival", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01690390"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Overall Survival is assessed via calculation of the time to death due to any cause. If a participant is known to have died, the time to death is defined as the time from the date of randomization to the date of death. Otherwise, a participant will be censored at the last date they are known to be alive.", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "15 months"
            }, 
            {
                "description": "Number of participants with an stable disease previously achieve complete response or partial response after dose escalation. Either complete response (CR) or partial response (PR) will be evaluated by RECIST, confirmed at least 28 days following the date of the initial response.", 
                "measure": "Transformation rate from stable disease to complete response or partial response", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "Number of patients with a adverse event, identified according to the Common Toxicity Criteria (CTC) in evaluable-for-safety population, which included all patients who received at least 1 dose of study medication.", 
                "measure": "Incidence rate of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "40 months"
            }
        ], 
        "source": "Betta Pharmaceuticals Co.,Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Betta Pharmaceuticals Co.,Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}